Key result
Antiplatelet therapy for secondary stroke prevention requires optimization based on individual patient risk.
Why the study?
Optimization of antiplatelet therapy for secondary stroke prevention requires evidence-based assessment of different regimens and individual patient risk.
How can antiplatelet regimens be optimized for secondary stroke prevention based on patient risk assessment?
How can antiplatelet regimens be optimized for secondary stroke prevention based on patient risk assessment?
This review highlights the importance of optimizing antiplatelet regimens, including aspirin and clopidogrel, for secondary stroke prevention based on individual patient risk assessment.
Answers are grounded in this paper and cite their sources.
Supports risk-stratified antiplatelet use post-stroke; leaves open prospective validation of specific regimens.
Role of antiplatelet therapy in secondary stroke prevention is of major significance. Antiplatelet agents predominantly in use are aspirin, clopidogrel, and combination regimes. The review focuses on the optimization of antiplatelet regimen based on evidence obtained from randomized-controlled trials, on different antiplatelet regimes and the risk assessment that may be unique to each patient.
No takes yet. Share an insight, caveat, or question.
M.V. Padma Srivastava (2010) studied this question. Antiplatelet therapy for secondary stroke prevention, predominantly aspirin and clopidogrel, requires optimization based on individual patient risk assessment and clinical trial evidence.
Synapse has enriched 10 related papers. Consider them for comparative context: